论文部分内容阅读
目的分析干扰素α-2b联合炎琥宁治疗小儿手足口病的疗效及安全性。方法选取2015年1月—2017年2月收治的80例手足口病患儿为研究对象,采用随机数字表法分为两组,给予对照组患儿利巴韦林治疗,给予观察组患儿干扰素α-2b联合炎琥宁治疗,对比两组临床疗效。结果观察组临床治疗总有效率为97.5%,显著高于对照组的75%,差异有统计学意义(P<0.05);观察组患儿不良反应发生率为0.0%,显著低于对照组的22.5%,差异有统计学意义(P<0.05)。结论干扰素α-2b联合炎琥宁治疗小儿手足口病的疗效显著,安全性高,值得广泛推广。
Objective To analyze the efficacy and safety of interferon α-2b in combination with midazolam in the treatment of hand-foot-mouth disease in children. Methods Eighty HFMD children were enrolled in this study from January 2015 to February 2017. The patients were divided into two groups according to the random number table. The patients in the control group were treated with ribavirin, and the children in the observation group Interferon alfa-2b combined with Yan Hu Ning treatment, the clinical efficacy of two groups were compared. Results The total effective rate of clinical observation in the observation group was 97.5%, which was significantly higher than that in the control group (P <0.05). The incidence of adverse reactions in the observation group was 0.0%, which was significantly lower than that in the control group 22.5%, the difference was statistically significant (P <0.05). Conclusions Interferon alfa-2b and mesylate are effective in treating hand-foot-mouth disease in children and are safe and worthy of widespread application.